How much longer will the popular weight loss medications be in shortage, and what happens in your med spa when they can no longer be compounded? This week, AmSpa founder and CEO, Alex R. Thiersch, JD, is joined by Sam Pondrom, JD, associate at national healthcare law firm ByrdAdatto. They talk about the recent availability status updates for tirzepatide and semaglutide, and what changes medical spas can anticipate when the brand-name medications become fully available. Listen to hear more about:

• What the latest changes in the status of tirzepatide availability mean and don’t mean;
• How the FDA determines whether a drug is still in shortage;
• The patent exception during shortage that clears the way for compounding pharmacies;
• Patent and intellectual property protection: how to safely market medical weight loss solutions;
• What to expect when these medications are officially taken off the drug shortage list;
• The future conversations you will need to have with your patients.

Catch up on AmSpa’s coverage for the changing tirzepatide status and semaglutide usage in med spas.

Music by Ghost Score